ANAB Earnings Date: Nov 3, 2026 (Estimated) — AnaptysBio, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ANAB's next earnings date?
AnaptysBio, Inc. (ANAB) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.84 on revenue of $25.6M.
How did ANAB do in its last earnings report?
In its most recent report on Sep 21, 2026 (Q2 2026), AnaptysBio, Inc. posted EPS of -$0.11 versus the $5.11 estimate, a miss of 76.1%. Revenue was $27.5M against a $27.5M estimate. The stock's 1-day post-earnings move was -1.8%.
How much does ANAB stock move after earnings?
ANAB beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.4% (up or down) in the day after earnings.
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-21 | Q2 2026 | 5.11 | -0.11 | +76.09% | $27.5M | ❌ Miss | -1.82% | -7.50% | -17.28% |
| 2026-05-12 | Q1 2026 | -0.66 | -1.84 | -178.79% | $25.6M | ❌ Miss | -4.41% | -8.86% | -17.29% |
| 2026-03-03 | Q4 2025 | 0.92 | 1.58 | +71.74% | $108.2M | ✅ Beat | +14.63% | +17.38% | +7.38% |
| 2025-11-04 | Q3 2025 | -1.17 | 0.52 | +144.44% | $76.3M | ✅ Beat | +3.63% | -3.41% | +24.61% |
| 2025-08-06 | Q2 2025 | -1.55 | -1.34 | +13.55% | $22.3M | ✅ Beat | -9.59% | -8.06% | -2.80% |
| 2025-05-05 | Q1 2025 | -1.46 | -1.28 | +12.33% | $27.8M | ✅ Beat | -2.97% | -3.40% | +2.60% |
| 2025-02-27 | Q4 2024 | -1.74 | -0.72 | +58.62% | $43.1M | ✅ Beat | +2.56% | +0.00% | +15.55% |
| 2024-11-05 | Q3 2024 | -1.65 | -1.14 | +30.91% | $30.0M | ✅ Beat | +11.70% | +8.15% | +19.02% |
Showing last 8 quarters.